Morphin Hexal (Morphine Sulfate)

Morphine binds to μ‑opioid receptors in the brain and spinal cord, acting as a full agonist. This binding inhibits the release of excitatory neurotransmitters, reduces neuronal firing in pain pathways, and raises the pain threshold, resulting in analgesia and often sedation.

The dose of Morphin Hexal is individualized and must be determined by a qualified prescriber based on the patient’s pain severity, prior opioid exposure, age, weight, organ function, and other clinical factors. No standard dosing regimen is provided here.

Data on the safety of morphine during pregnancy and lactation are limited. Because opioids can cross the placenta and enter breast milk, the product is generally avoided unless the potential benefit justifies the potential risk. Consultation with a specialist is essential.

To request Morphin Hexal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Morphin Hexal contains morphine sulfate, a benchmark opioid with well‑characterized efficacy and safety. Compared with alternatives such as fentanyl or hydromorphone, morphine has a longer history of use, a broader therapeutic window, and is available in multiple injectable routes, but it may have a higher incidence of certain side effects like constipation.

Morphin Hexal should be stored at room temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations. Do not freeze or expose to excessive heat, and keep out of reach of children.

Morphin Hexal is supplied for parenteral use and can be given via epidural, intramuscular, or intrathecal injection. Administration must be performed by qualified healthcare professionals following aseptic technique and appropriate dosing guidelines for the selected route.

The most critical risks include respiratory depression, severe hypotension, and anaphylactic reactions. These events can be life‑threatening and require immediate medical attention. Patients should be closely monitored, especially during initiation, dose escalation, or when combined with other depressant agents.

Morphin Hexal is contraindicated in patients with known hypersensitivity to morphine or any component of the formulation, those with significant respiratory depression, acute or severe bronchial asthma, and in individuals who have taken MAO inhibitors within the past 14 days. Caution is also advised for patients with uncontrolled head injury or increased intracranial pressure.